SNC Therapeutics, Inc.
Evanston, IL
- UEI
- YNQPL17KGWA6
- CAGE
- 253M3
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1801 Maple Ave #1400, Evanston, IL 60201, USA
- Website
- snctherapeutics.com
- Founded
- 2022
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $6,997,810 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $6,997,810 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Arpa-H SNC quiet sttr phase II | Interior Business Center (DO) | $3,499,423 | |
| Arpa-H SNC shield sttr phase II | Interior Business Center (DO) | $3,498,387 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Tolerogenic nanotherapy to delay type I diabetes | National Institute of Diabetes and Digestive and Kidney Diseases (NIH) | $700,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Qrono, Inc. | Pittsburgh, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Exomira Medicine Inc. | Chicago, IL | — |
| Celdara Medical, LLC | Lebanon, NH | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Gentibio, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Astero Erado Inc. | College Station, TX | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
SNC Therapeutics, Inc., a Black American-owned, minority-owned small business based in Evanston, Illinois, develops tolerogenic nanotherapies for autoimmune diseases as a prime recipient of federal research contracts and grants from the National Institutes of Health, operating exclusively as a direct recipient with no subcontract footprint.
The vendor's recent federal footprint comprises three awards totaling $7 million in combined potential value, all from the National Institutes of Health. Two awards are ARPA-H–funded STTR Phase II definitive contracts awarded September 24, 2026, with ultimate completion dates of September 27, 2028: the ARPA-H SNC Quiet STTR Phase II contract ($3,499,423) and the ARPA-H SNC Shield STTR Phase II contract ($3,498,387), both performed in Evanston under total small business set-asides on firm fixed-price terms. The third award is a research grant from the National Institute of Diabetes and Digestive and Kidney Diseases, dated July 25, 2025, with ultimate completion in July 2026. The grant-funded work centers on tolerogenic nanotherapy to delay Type 1 diabetes, developing rapamycin-loaded polymersomes for selective delivery to antigen-presenting cells as a preventative treatment for T1D onset, with preliminary results published in Nature Nanotechnology.
Dr. Scott, principal investigator at Northwestern University and founder and CEO of SNC Therapeutics, leads the research effort. All awards are concentrated with the National Institutes of Health (100% of customer awards by count and potential value). Two awards—the two STTR Phase II contracts—expire within the next twenty-four months and face recompete, representing $7 million in recompete exposure. The vendor operates under small business set-asides across its current footprint and has no history of parent vehicle participation, IDV membership, or subcontractor engagement in recent federal work.
Quick answers
Is SNC Therapeutics, Inc. registered in SAM.gov?
Yes. SNC Therapeutics, Inc.'s SAM.gov registration is active through September 8, 2027.
What is SNC Therapeutics, Inc.'s CAGE code?
SNC Therapeutics, Inc.'s CAGE code is 253M3, and its Unique Entity ID (UEI) is YNQPL17KGWA6.
How much has SNC Therapeutics, Inc. received in federal contracts?
Federal contracts obligated $6,997,810 to SNC Therapeutics, Inc. in fiscal years 2023 through 2027.
What is SNC Therapeutics, Inc.'s most recent federal award?
SNC Therapeutics, Inc.'s most recent federal contract award is Arpa-H SNC quiet sttr phase II (140D0426C0123), from Interior Business Center (DO), on September 24, 2026.
On GovTribe
See SNC Therapeutics, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors